文献速递姑息放疗与转移瘤

疼痛性肿瘤患者分类预测姑息性放射治疗反应

Classification of Patients With Painful Tumors to Predict Response to Palliative Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-03-15

这项前瞻性观察研究纳入261例患者共366个可评估病灶,评估姑息性放疗后12周疼痛缓解率,并依据阿片类药物使用和再程放疗将病灶分为3类,各类12周缓解率分别为75%、61%和36%(P < .001),24周进展率分别为11%、27%和63%(P < .001)。

要点

  • 阿片类药物使用和再程放疗是多因素分析中影响疼痛缓解率的负面因素(P < .01)。
  • 分类1(无阿片类药物使用且无再程放疗)89个病灶,12周缓解率75%。
  • 分类3(使用阿片类药物且再程放疗)66个病灶,12周缓解率36%,24周进展率63%。

核心结论

  • 阿片类药物使用和再程放疗是导致疼痛缓解率和进展时间显著差异的因素。

研究设计与样本

  • 前瞻性观察研究(UMIN000044984),纳入2021年8月至2022年9月接受姑息性放疗且治疗前数字评分量表(NRS)≥2分的疼痛性肿瘤患者,随访计划为放疗后2、4、12、24、36和52周。

主要发现

  • 488个登记病灶中366个来自261例患者符合标准,大多数为骨转移(75%),其中72%使用阿片类药物,22%接受再程放疗。
  • 93%的患者接受常规放疗(例如8 Gy单次、20 Gy分5次),中位随访6.8个月,273个可评估病灶平均NRS从6.1降至12周时3.4,缓解率60%。
  • 多因素分析显示阿片类药物使用和再程放疗对缓解率有负面影响(P < .01)。
  • 分类1(无阿片类药物使用且无再程放疗;89个病灶)、分类2(既非分类1也非分类3;211个病灶)、分类3(使用阿片类药物且再程放疗;66个病灶)的缓解率分别为75%、61%和36%(P < .001)。
  • 各分类间至缓解时间相似(P = .91),但24周进展率不同(分别为11%、27%和63%;P < .001)。

关键数值与推荐

  • 疼痛反应采用国际共识疼痛反应终点标准评估,主要结局为12周内缓解率。
  • 分类1:无阿片类药物使用且无再程放疗,89个病灶,缓解率75%,24周进展率11%。
  • 分类2:既非分类1也非分类3,211个病灶,缓解率61%,24周进展率27%。
  • 分类3:使用阿片类药物且再程放疗,66个病灶,缓解率36%,24周进展率63%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to identify factors affecting pain response to develop a patient classification system for palliative radiation therapy (RT). METHODS AND MATERIALS: Our prospective observational study (UMIN000044984) provided data on patients who received palliative RT for painful tumors. The eligibility criteria were having a numerical rating scale (NRS) score of 2 or more before treatment and receiving palliative RT between August 2021 and September 2022. Post-RT follow-up was scheduled prospectively at 2, 4, 12, 24, 36, and 52 weeks. Pain response was assessed using the International Consensus Pain Response Endpoints criteria, with the primary outcome being the response rate within 12 weeks. Multivariable logistic regression was performed to identify factors affecting pain response and develop the classification system. Each class evaluated the differences in response rate, time to response, and progression. RESULTS: Of the 488 registered lesions, 366 from 261 patients met the criteria. Most patients had bone metastases (75%), of whom 72% were using opioids and 22% underwent reirradiation. Conventional RT (eg, 8-Gy single fraction, 20 Gy in 5 fractions) was administered to 93% of patients. Over a median of 6.8 months of follow-up, the average NRS decreased from 6.1 to 3.4 at 12 weeks for 273 evaluable lesions, with a 60% response rate. Opioid use and reirradiation negatively affected the response rate in multivariate analysis (P < .01). Lesions were categorized into class 1 (no opioid use and no reirradiation; 89 lesions), class 2 (neither class 1 nor 3; 211 lesions), and class 3 (opioid use and reirradiation; 66 lesions), with respective response rates of 75%, 61%, and 36% (P < .001). Time to response was similar across the classes (P = .91), but the progression rates at 24 weeks differed (11%, 27%, and 63%, respectively; P < .001). CONCLUSIONS: Opioid use and reirradiation are factors leading to significant variations in pain response rates and time to progression.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Koide Y, Shindo Y, Nagai N, et al. Classification of Patients With Painful Tumors to Predict Response to Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024. PMID: 38493900. doi:10.1016/j.ijrobp.2024.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。